Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Ashish Sanil"'
Autor:
HS Han, Christina Yau, Jane Perlmutter, Amy Wilson, Heather Beckwith, Anne M. Wallace, Tara Sanft, Ashish Sanil, Erica Stringer-Reasor, Laura J. Esserman, Zahi Mitri, Donald A. Berry, Rita Nanda, Claudine Isaacs, Alexandra Thomas, Kevin Kalinsky, Hope S. Rugo, Michelle E. Melisko, A. Jo Chien, Smita Asare, W. Fraser Symmans, Judy C. Boughey, Douglas Yee, Laura J. van't Veer, Kathy S. Albain, Amy S. Clark, Julie E. Lang, Anthony D. Elias, Nola M. Hylton, Angela DeMichele, Shi Wei, Richard Schwab
Publikováno v:
Cancer Research. 81:PD1-10
Background: I-SPY 2 is a multicenter, phase 2 trial using response-adaptive randomization within molecular subtypes defined by receptor status and MammaPrint (MP) risk to evaluate novel agents as neoadjuvant therapy for women with high-risk stage II/
Autor:
Amy Wilson, Erica Stringer-Reasor, Jane Perlmutter, Christina Yau, Donald A. Berry, Kevin Kalinsky, Ashish Sanil, Kathy S. Albain, Hope S. Rugo, Teresa Helsten, Amy S. Clark, Laura J. Esserman, Erin D. Ellis, Angela DeMichele, Richard Schwab, Anthony D. Elias, Smita Asare, Nola M. Hylton, Michelle E. Melisko, Claudine Isaacs, Anne M. Wallace, Judy C. Boughey, Ruby Singhrao, Janice Lu, Douglas Yee, Julie E. Lang, Shelly S. Lo, Laura J. van't Veer, A. Jo Chien, W. Fraser Symmans
Publikováno v:
Cancer Research. 80:P3-11
Background: I-SPY2 is a multicenter, phase 2 trial using response-adaptive randomization within biomarker subtypes to evaluate novel agents as neoadjuvant therapy for high-risk breast cancer. The primary endpoint is pathologic complete response (pCR)
Autor:
Ruby Singhrao, Jane Perlmutter, Angela DeMichele, A. Jo Chien, Christina Yau, HS Han, Donald A. Berry, Patricia A. Robinson, W. Fraser Symmans, Kevin Kalinsky, Laura J. Esserman, Richard Schwab, Anne M. Wallace, Erica Stringer-Reasor, Kathy S. Albain, Patricia K Haugen, Tara Sanft, Amy S. Clark, Ashish Sanil, Smita Asare, Laura J. van't Veer, Kathleen Kemmer, Hope S. Rugo, Amy Wilson, Janice Lu, Julie E. Lang, Minetta C. Liu, Anthony D. Elias, Nola M. Hylton, Rita Nanda, Claudine Isaacs, Douglas Yee, Michelle E. Melisko, Judy C. Boughey
Publikováno v:
Cancer Research. 80:P3-09
Background: I-SPY2 is a multicenter, response-adaptive randomization phase 2 trial to evaluate novel agents when added to standard neoadjuvant therapy for women with high-risk stage II/III breast cancer - weekly paclitaxel + investigational treatment
Autor:
Melissa Paoloni, A Magliocco, W Yang, AD Elias, Mark A. Rosen, H Sattar, AS Clark, Jane Perlmutter, Gillian L. Hirst, Sy Chui, KA Ward, Richard Schwab, Anne M. Wallace, B Chen, AM DeMichele, Michael D. Nelson, Michael Feldman, L.J. van 't Veer, Scott M. Berry, Y-Y Chen, Amy Wilson, Larissa A. Korde, Lajos Pusztai, Haydee Ojeda-Fournier, O Fadare, Brian Datnow, W K Bernreuter, PK Haugen, H Abe, Rebecca K. Viscusi, M. Melisko, K Oh, Molly Klein, W Li, Julia L. Clennell, C Yau, S. L. Moulder, G Krings, Judy C. Boughey, Rita Nanda, David M. Euhus, Heather Beckwith, Heidi Umphrey, S Wei, Nola M. Hylton, C Isaacs, Donald A. Berry, Ruby Singhrao, AJ Chien, William Fraser Symmans, Erica Stringer-Reasor, Erin D. Ellis, Qamar J. Khan, S Yang, O. I. Olopade, P Mhawech-Fauceglia, Meredith Buxton, Jeffrey B. Matthews, T Vinh, Hyo S. Han, Adam Asare, M Rendi, C Hatzis, Shelly S. Lo, Janice Lu, Donald W. Northfelt, Debu Tripathy, Pulin Sheth, DH Bang, Dulcy Wolverton, Bethany L. Niell, K Adamson, Ashish Sanil, HS Rugo, Kathy R. Brandt, S Sams, Je Lang, Mohammad Eghtedari, Teresa Helsten, S Sahoo, William C. Wood, Minetta C. Liu, Katherine Steeg, John W. Park, A Ferero-Torres, Erin P. Crane, J Zeck, Douglas Yee, A Adams, Ossama Tawfik, L Grasso LeBeau, Stefan E. Pambuccian, I Ocal, Kathleen Kemmer, KS Albain, Basak E. Dogan, Bonnie N. Joe, Kirsten K. Edmiston, LJ Esserman, Garry Peterson, S Asare, Shuko Harada
Publikováno v:
Cancer Research. 79:P2-07
Background: Patients achieving a pathologic complete response (pCR) following neoadjuvant therapy have significantly improved event-free survival relative to those who do not; and pCR is an FDA-accepted endpoint to support accelerated approval of nov
Autor:
Beverly Kyalwazi, Christina Yau, Olufunmilayo Olopade, A. Jo Chien, Anne Wallace, Andres Forero-Torres, Lajos Pusztai, Erin Ellis, Kathy Albain, Anne Blaes, Barbara Haley, Judy Boughey, Anthony Elias, Amy Clark, Claudine Isaacs, Rita Nanda, Hyo Han, Rachel Yung, Debu Tripathy, Kristen Edmiston, Rebecca Viscusi, Donald Northfelt, Qamar Khan, Ashish Sanil, Scott Berry, Smita Asare, Amy Wilson, Gillian Hirst, Nola Hylton, Michelle Melisko, Jane Perlmutter, Hope Rugo, Fraser Symmans, Laura van ‘t Veer, Donald Berry, Laura Esserman
Publikováno v:
Cancer Research. 82:GS4-02
Background Transcriptomic immune-related gene signatures have been associated with achievement of pathologic complete response (pCR) and prognosis in the neoadjuvant setting. I-SPY 2 is a multicenter, phase 2 platform trial using response-adaptive ra
Autor:
S Asare, D Yee, LJ Esserman, Ruby Singhrao, Christina Yau, Rita Nanda, Denise M. Wolf, AM DeMichele, Deborah L. Berry, Lamorna Brown-Swigart, Gillian L. Hirst, Ashish Sanil, M Liu, L van 't Veer, I-Spy Trial Investigators
Publikováno v:
Cancer Research. 78:PD6-14
Background: Pembrolizumab (P), an anti-PD-1 immune checkpoint inhibitor, has been approved for treatment of microsatellite instability-high and mismatch repair deficient cancers. In I-SPY 2, patients were randomized to receive standard chemotherapy a
Autor:
Je Lang, Judy C. Boughey, Christina Yau, S. L. Moulder, AD Elias, Barbara Haley, L.J. van 't Veer, Kathy S. Albain, Ashish Sanil, AM DeMichele, Hank Kaplan, Susan Minton, Rita Nanda, Claudine Isaacs, Donald A. Berry, Julia Lyandres, LJ Esserman, Jane Perlmutter, Melissa Paoloni, Meredith Buxton, Kathleen Kemmer, Nola M. Hylton, Amy Jo Chien, William Fraser Symmans, Anne M. Wallace, D Yee, Andres Forero, Larissa A. Korde, Michael Hogarth
Publikováno v:
Cancer Research. 77:P6-11
Background:Pathologic complete response(pCR) after neoadjuvant therapy is an established prognostic biomarker for high-risk breast cancer(BC). Improving pCR rates may identify new therapies that improve survival. I-SPY 2 uses response-adaptive random
Autor:
Christina Yau, Kathleen Kemmer, Susan Minton, Meredith Buxton, Judy C. Boughey, LJ Esserman, S. L. Moulder, Anne M. Wallace, AM DeMichele, William Fraser Symmans, L.J. van 't Veer, Kathy S. Albain, Donald A. Berry, Jane Perlmutter, Barbara Haley, Nola M. Hylton, AD Elias, Rita Nanda, Claudine Isaacs, Julia Lyandres, Melissa Paoloni, Larissa A. Korde, Amy Jo Chien, Michael Hogarth, Hank Kaplan, D Yee, Andres Forero, Je Lang, Ashish Sanil
Publikováno v:
Cancer Research. 77:P6-11
Background: I-SPY 2 is a multicenter, phase 2 trial using response-adaptive randomization within biomarker subtypes to evaluate novel agents when added to standard neoadjuvant therapy for women with high-risk stage II/III breast cancer - investigatio
Autor:
Gillian L. Hirst, Fraser Symmans, HS Rugo, LJ Esserman, Meredith Buxton, L van 't Veer, O. I. Olapade, AM DeMichele, Nola M. Hylton, Denise M. Wolf, Annuska M. Glas, C Petricoin, I-Spy Trial Investigators, Christina Yau, D Yee, Melissa Paoloni, Julie Wulfkuhle, Ashish Sanil, Deborah L. Berry, Lamorna Brown-Swigart
Publikováno v:
Cancer Research. 77:S2-06
Background: The PARP inhibitor veliparib in combination with carboplatin (VC) was one of the experimental regimens evaluated in the phase 2 neoadjuvant I-SPY 2 standing trial for high risk breast cancer patients. VC graduated in the triple negative (
Autor:
AM DeMichele, L van 't Veer, Fraser Symmans, Christina Yau, LJ Esserman, KS Albain, Nola M. Hylton, J Lyandres Clennell, Melissa Paoloni, I-Spy Trial Investigators, Meredith Buxton, Brian Leyland-Jones, Deborah L. Berry, D Yee, Ashish Sanil
Publikováno v:
Cancer Research. 76:P1-14
Background: I-SPY 2 is a multicenter phase 2 trial using response-adaptive randomization within biomarker subtypes to evaluate a series of novel agents when added to standard neoadjuvant therapy for women with high-risk stage II/III breast cancer. Th